We evaluated whether long-term (2 months) administration of interleukin-7 (IL7) hastens immune recovery in baboons rendered severely lymphopenic by total body irradiation and antithymocyte globulin (ATG). Four baboons were treated with recombinant baboon IL7 and three baboons with placebo. Median CD4 T cell count at the end of IL7/placebo treatment was higher in the IL7-treated animals (2262 vs. 618/Al, P = 0.03). This appeared to be a result of peripheral expansion rather than de novo generation. Median cytomegalovirus (CMV)-specific IFNg-producing CD4 T cell count at the end of IL7/placebo treatment was higher in the IL7-treated animals (122 vs. 1/Al, P = 0.03). All animals were pretransplant cytomegalovirus-seropositive. One animal died at the end of IL7 treatment; necropsy showed extensive T cell infiltration of kidneys and lungs. In conclusion, IL7 stimulates the expansion of CD4 T cells, including functional antiviral cells. Clinical risk-benefit ratio needs to be evaluated.
Introduction
CD4 T-lymphopenia in hematopoietic cell transplant recipients and HIV-infected patients is associated with infections [1] [2] [3] , including cytomegalovirus (CMV) infections [4, 5] . IL7 has been shown to increase CD4 T cell counts in both murine and nonhuman primate models [6] [7] [8] [9] [10] [11] . Both de novo generation of T cells (from hematopoietic cells, typically in the thymus) and peripheral expansion of existing T cells were reported to be stimulated by IL7 in mice [9] . However, only peripheral expansion was stimulated in the two primate studies reported, that is, Fry et al.'s [10] study using normal and SIV-infected macaques and our study using irradiated baboons [11] . It is possible that de novo generation was not observed in the two primate studies because the treatment was too short (10 days in Fry et al.'s study and 28 days in our study), because xenogeneic IL7 was used or because only moderately lymphopenic monkeys were treated.
The present study was thus performed for the following reasons: (1) to study the effect of IL7 in severely lymphopenic monkeys, as stimulation of de novo generation by IL7 was not observed in T cell-replete mice [12] ; (2) to administer baboon instead of human IL7, as baboonantihuman IL7 antibodies [11] or, less likely, relative incompatibility between human IL7 and baboon IL7 receptor could diminish the IL7 effect; (3) to treat the animals for a longer period (8 weeks) than in the previous studies; as thymocyte precursor to T cell differentiation takes at least 12 days [13] , only prolonged treatment might result in a detectable rise of recent thymic emigrants, represented by T cell receptor excision circle-containing (TREC + ) T cells; (4) to add data on potential side effects of IL7 in primates, as clinical trials of IL7 in patients with iatrogenic or HIV-induced lymphopenia are being planned; (5) most important, to determine whether the IL7-stimulated increase in the total CD4 T cell counts might be functionally relevant. To evaluate this, we treated CMV-seropositive baboons and asked whether higher anti-CMV CD4 T cell counts were achieved in the IL7 than placebo-treated animals. Reconstitution of anti-CMV CD4 T cells is essential for the reconstitution of anti-CMV CD8 T cells (reviewed by Gratama and Cornelissen [14] ), and increased numbers of CMV-specific CD4 T cells have been associated with decreased incidence of symptomatic CMV disease [15] .
Materials and methods

Study design and animals
Seven male baboons (Papio cynocephalus anubis), age 2 years (equivalent to 5-7 human years [16] [17] [18] ), underwent total body irradiation (TBI, 10.2 Gy) followed by autologous transplantation of CD34 cells marked with yellow fluorescent protein (YFP) gene. Before starting IL7/placebo treatment, T cells were further depleted by antithymocyte globulin (ATG, thymoglobulin, 5 mg/kg intravenously on days 32, 34, 36, and 39 posttransplant, kindly donated by Sangstat, Fremont, CA). Importantly, in vivo ATG causes apoptosis of circulating splenic and lymphonodal T cells but does not affect thymocytes, probably because of limited access of ATG to the thymus [19] . Three baboons received placebo, and four baboons received recombinant baboon IL7 (kindly donated by Cytheris, Vanves, France) 80 Ag/kg once a day subcutaneously from days 42 to 98 after transplantation. In the Results, day 42 is referred to as bimmediately pre-IL7/placebo treatmentQ and day 98 as bweek 8 of treatment.Q Lyophilized recombinant baboon IL7 was reconstituted with a diluent containing 4 mg/ml sucrose and 125 mM sodium citrate, pH 6.2. The same diluent was used as placebo. Pretransplant, the animals were seropositive for CMV, seronegative for Babesia and STLV-I, and tuberculin test-negative. They were housed and cared for at the University of Washington Regional Primate Research Center under conditions approved by the American Association for the Accreditation of Laboratory Animal Care. The study was approved by the UW Animal Care and Use Committee and the FHCRC Institutional Review Board.
Transplantation and posttransplant treatment
Filgrastim (G-CSF), 100 Ag/kg daily, and stem cell factor (SCF), 50 Ag/kg daily, were given subcutaneously from days 8 to 4 to increase the number of CD34 cells in the marrow. On day 3, bone marrow was harvested into preservative-free heparin from both humeri and femora. CD34 cells were immunomagnetically enriched to approximately 80% purity, using antibody 12.8 and goat antimouse IgM-coated microbeads (Miltenyi, Auburn, CA). Transduction of CD34 cells with an oncoretrovirus carrying the enhanced YFP gene was done as described [20] . Approximately 50% transduced and 50% untransduced CD34 cells were infused. (The utility of transplanting the YFP gene-transduced CD34 cells was limited, as sustained engraftment of the transduced cells was achieved in only four of the seven animals.) After total body irradiation (10.2 Gy in two fractions at 0.07 Gy/ min), the cells were reinfused on day 0. Supportive care included irradiated whole blood transfusions for thrombocytopenia and prophylactic antibiotics (acyclovir and fluconazole from days 0 to 112, ceftazidime + gentamycin + vancomycin from days 0 to 41 and levofloxacin from days 41 to 112 posttransplant).
Enumeration of blood mononuclear cell subsets
Mononuclear cells (MNCs) were separated from EDTAanticoagulated blood using density gradient (Ficoll, density 1.073 kg/l) centrifugation. The cells, suspended in flow buffer (PBS with 1% bovine serum albumin and 0.1% sodium azide), were stained with fluorochrome-conjugated monoclonal antibodies and analyzed by five-color flow cytometry. The following antibodies were used: CD3 from Biosource (clone FN18), CD4 from BD Biosciences (clone SK3), CD8 from Beckman-Coulter (clone B9.11), CD11a from Beckman-Coulter (clone 25.3.1), CD14 from Beckman-Coulter (clone RMO52), CD16 from Beckman-Coulter (clone 3G8), CD20 from BD Biosciences (clone L27), CD45RA from Beckman-Coulter (clone ALB11), and CD56 from Beckman-Coulter (clone N901). Residual red blood cells were lysed in hemolytic buffer (8.3% ammonium chloride + 1% potassium bicarbonate + 0.4% EDTA). No fixation was done. Cells were resuspended in flow buffer and kept on ice until flow cytometry, which occurred within 12 h from blood drawing. FACSCalibur (BD Biosciences) flow cytometer was used for data acquisition. List-mode data were analyzed using WinList software (Verity Software House, Topsham, ME). The FSc Â SSc gate was set to encompass MNCs. B cells were defined as CD20 + MNCs. CD4 T cells were defined as CD3 + CD4 + MNCs, and CD8 T cells were defined as CD3 + CD8 + MNCs. NK cells were defined as MNCs expressing CD16 or CD56 and not expressing CD3 or CD14. Monocytes were defined as CD14 + MNCs. Each absolute MNC subset count was calculated as the absolute MNC count multiplied by the percent of the MNC subset divided by 100. The absolute MNC count represented the sum of absolute lymphocyte count and absolute monocyte count determined by our clinical hematology laboratory, using Sysmex XE2100 cell counter and Giemsa-stained blood smears.
Lymph nodes (LN) were obtained immediately before starting IL7 (right axilla) at week 8 of treatment (left axilla) and approximately 3 months later (right axilla). Axillary LNs were chosen as they were distant from the IL7/placebo injection sites (thighs). The LNs were teased in RPMI with 10% fetal calf serum. The resulting cell suspension was filtered through a 70-Am nylon cell strainer. Percentages of cell subsets were determined by flow cytometry as in the blood.
Thymic biopsy was done in one placebo-treated and two IL7-treated animals at week 8 of treatment, using upper sternal split approach under general anesthesia. Approximately 3000 mm 3 of thymic tissue was removed and processed for flow cytometry as for lymph nodes and for histology as described below.
CMV serology
The presence of antibodies against baboon CMV was tested by Simian Diagnostic Laboratory (San Antonio, TX) using rapid dot-immunobinding assay [21] . In brief, virus or control antigens were spotted on the nitrocellulose sheet and allowed to absorb for 30 min at room temperature. Then the nitrocellulose sheet was submerged in 5% nonfat milk in PBS to block nonspecific binding for 1 h followed by washing with PBS-Tween (0.1%). After test sera were applied over the test antigen dots, the nitrocellulose sheet was incubated for 1 h at 378C and then washed three times in PBS-Tween. Then staphylococcal protein A-conjugated horseradish peroxidase was used to detect primate IgG. Following incubation and washing, the substrate, 4-chloro-1-naphthol-hydrogen peroxide, was used, and a blue spot was developed as a positive result. Controls consisted of uninfected cell culture antigens and known positive and negative sera.
Intracellular cytokine staining for detection of CMV-specific CD4 T cells
We used CMV lysate to stimulate baboon MNCs. CMV lysate was prepared using MRC5 human lung fibroblast cell line (ATCC CCL-171) infected with baboon CMV, strain PGH-01 (ATCC VR-1530) or OCOM4-37 (kindly provided by Dr. Earl Blewett, Oklahoma State University). After infection had progressed to N90% cytopathic effect, the cells were harvested and subjected to multiple freeze-thaw cycles. Then the cells were washed twice in glycinebuffered saline, and the pellets were sonicated on ice. The resulting suspension of cell organelles/particles was centrifuged at 2000 rpm for 10 min, and the supernatant was harvested. The supernatants from both CMV strains were mixed and heat-inactivated at 568C for 30 min. Protein concentration was determined with a BCA protein assay kit (Pierce, Rockford, IL). Aliquots of the CMV lysate were stored in À808C. Control lysate with the same protein concentration was prepared from uninfected MRC5 cells.
One million PBMC in 1 ml of RPMI 1640 supplemented with 2 mM glutamine, 25 mM HEPES, 10% fetal bovine serum (Hyclone, Logan, UT) were incubated with CMV lysate (5 Ag protein/ml), uninfected MRC5 lysate (5 Ag protein/ml, negative control), or staphylococcal enterotoxin B (1 Ag/ml, Sigma, positive control) in the presence of anti-CD28 and anti-CD49d antibodies (0.5 Ag/ml each, BD Biosciences, San Jose, CA) overnight at 378C in a humidified atmosphere. Brefeldin A (10 Ag/ml; SigmaAldrich, St. Louis, MO) was added 2 h after the initiation of the culture. After the overnight incubation, cells were treated with 1 mM EDTA for 10 min at RT. Then the cells were sequentially fixed and permeabilized using FACS lysing solution and FACS permeabilizing solution (BD Biosciences). The cells were then stained with anti-IFNgphycoerythrin (clone 45.15, Beckman Coulter [Immunotech], Miami, FL) or anti-TNFa-phycoerythrin (clone Mab11, BD Biosciences), anti-CD3-PerCPCy5.5 (clone SK34-2, BD Biosciences), anti-CD8 APCCy7 (clone SK1, BD Biosciences), and anti-CD4-APC (clone SK3, BD Biosciences) for 30 min at room temperature in the dark. After final wash with flow buffer, data acquisition was done on LSR II cytometer (BD Biosciences). At least 200,000 events were acquired. Data were analyzed using FlowJo software (Treestar, San Carlos, CA).
Detection of CMV by PCR
DNA was extracted from 200 Al serum using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA). The following primers were used: 5V-TACGTCATTGG-TACCCTCC-3V(forward) and 5V-GGAGTACTGCCAATG-TACTA-3V(reverse) [22] . Each reaction contained 2.5 U platinum-Taq polymerase (Invitrogen, Carlsbad, CA), 2.5 mM MgCl 2 , 500 uM dNTPs, 500 nM each primer, 20 Al extracted DNA (of total 100 Al yielded by the QIAamp kit) in a total volume of 50 Al. The conditions of each reaction were 1 cycle of 958C for 9 min, followed by 40 cycles of 948C/60 s; 588C/60 s; 728C/60 s, and finally 1 cycle of 728C for 9 min. PCR products were separated on 2% agarose gel and visualized by ethidium bromide staining. As a positive control, we used DNA extracted from the CMV lysate (derived from baboon CMVinfected MRC5 cells). As negative control, we used DNA extracted from baboon lymphocryptovirus (EpsteinBarr virus-like virus)-transformed baboon B lymphoblastoid cells.
T cell receptor excision circle (TREC) assay
FACS-sorted CD4 T cell pellets of 200,000 cells were lysed in 40 Al of lysis buffer containing 100 Ag/ml proteinase K and 10 mM Tris-HCl (pH 8.0). The 5V-nuclease (Taqman) assay for the baboon ay signal joint TREC [11] was performed on 5 Al of cell lysate using forward primer, 5VCACATCCCTTTCAACCATGCT3V, reverse primer, 5VGCCAGCTGCAGGGTTTAGG3V, and probe FAM-ACGCATTTGGTTTTTGTAAAGGTGCT-CACT-QSY7 (MegaBases, Chicago, IL). PCR reactions contained 0.5 U Taq polymerase, 3.5 mM MgCl 2 , 0.2 mM dNTPs, 400 nM each primer, 200 nM probe, and Blue-636 reference (MegaBases). The reactions were run at 958C for 5 min, then 958C/30 s, and 608C/1 min for 40 cycles, using ABI7700 system (PE Biosystems, Norwalk, CT). Samples were analyzed in quadruplicates. Plasmids containing the baboon signal joint region were used as standards. A standard curve was plotted, and the TREC level (the number of TREC copies in 5 Al of cell lysate, which corresponds to 25,000 cells) was calculated using the ABI7700 software. The absolute count of TREC + CD4 (CD8) T cells (per microliter) was calculated as the TREC level (per 25,000 cells) multiplied by the absolute CD4 T cell count (per microliter) and divided by 25,000.
Computed tomography (CT)
Volumes of the thymus, the spleen, and the lymph nodes and the density of the cancellous bone of L3, L4, and L5 vertebrae were measured as described [11] . The calculated density of the torso phantom ranged from 94.6 to 96.7 mg/cm 3 , suggesting adequate reproducibility. The volume of the kidneys was determined analogously to the thymus. Briefly, the area of kidneys (mm 2 ) was determined on each slice, using IV contrast images and GE Pathspeed software (GE Medical Systems). The area was multiplied by the slice thickness (1.25 mm) to get the volume at that slice level (mm 3 ). Kidney volume (of both kidneys together) was calculated as the sum of the volumes at each slice level. Increase of volume of an organ was calculated as the volume at the end (week 8) of IL7/ placebo treatment minus the volume immediately pre-IL7/ placebo treatment.
Histology
Using standard techniques, 10% neutral buffered formalin-fixed, paraffin-embedded, and in the case of bone marrow, decalcified tissue sections were stained with hematoxylin and eosin (H and E) or immunostained with CD3 (rabbit-antihuman CD3 polyclonal antibody, Dako, Carpinteria, CA) or CD20 (clone L26, Dako). OTCembedded snap-frozen tissues were immunostained with CD4 (clone 1F6, Novocastra, Newcastle upon Tyne, UK) or CD8 (clone G10.1, kind gift of Dr. Bing Hu, University of Washington). Slides were analyzed by one pathologist (D.L.) blinded to IL7 versus placebo treatment. Bone marrow cellularity was estimated from the H and E-stained sections and expressed as the percentage of nonfat cells among fat plus nonfat cells. Percentage of T or B cells among bone marrow hematopoietic cells was estimated from the immunostained sections.
IL7 levels and IL7 neutralizing antibodies
Serum concentration of IL7 was determined by ELISA using the kit for human IL7 (R and D Systems, Minneapolis, MN). In case of values exceeding the concentration of the highest standard, diluted serum was used.
IL7 neutralizing antibodies were determined by the inhibition of the growth of IL7-dependent cells (PB1) as described [11] .
Statistics
To compare the counts of CD4 T cells or their subsets at the end of IL7/placebo treatment for the animals that survived until the week 8 evaluation, we used the average count from weeks 7 and 8 of the IL7/placebo treatment. For the animal that died 1 day before the week 8 evaluation (Z00158), we used the count from week 7. Significance of differences was tested by the Mann-Whitney-Wilcoxon rank sum test. As the hypothesis was that the cell counts were higher in the IL7-treated animals, one-tailed P value was used.
Results
IL7 treatment improved the reconstitution of CD4 T cells but not CD8 T cells
After total body irradiation and further T cell depletion by ATG, the baboons were severely lymphopenic. Immediately before starting IL7/placebo treatment, median CD4 T cell count in the blood was 3/Al, and lymph nodes were severely lymphocyte-depleted (composed of mostly histiocytes). At the end of IL7/placebo treatment (weeks 7-8), median CD4 T cell count in the blood was higher in the IL7-treated animals (2262 vs. 618/Al, P = 0.03) (Fig.  1) . The median number of weeks it took to reach individual pretransplant CD4 T cell count was 2.5 weeks for IL7-treated versus 8 weeks for placebo-treated animals ( P = 0.03). The improved CD4 T cell reconstitution appeared to be primarily, if not entirely, due to the stimulation of peripheral expansion, as the count of TREC + CD4 T cells (per microliter of blood which reflects thymic output irrespective of peripheral expansion [not the percent of TREC + cells among CD4 T cells which is influenced by peripheral expansion]) was not significantly higher in IL7 than placebo-treated animals (Fig. 1) . Both CD45RA high and CD45RA low/À CD4 T cell counts were significantly higher at the end of treatment (weeks 7-8) in IL7 than placebo-treated animals ( P = 0.03) (Fig.  1) . This, together with the fact that TREC + CD4 T cell counts were not significantly higher in the IL7-treated animals, suggests that IL7 induced expansion of both naive as well as memory/effector cells. The naive cells expanded by IL7 likely included cells generated de novo since the time of transplant; as in the four animals with sustained YFP marking (two IL7-and two placebotreated), there was a trend toward higher YFP + CD4 T cell counts at the end of treatment (weeks 7-8) in the IL7-than placebo-treated animals (median 294 vs. 68/Al, data not shown).
The increased blood CD4 T cell counts in IL7-treated animals were not due to redistribution of CD4 T cells from tissues to blood; as in the bone marrow of IL7-versus placebo-treated animals, there was a trend toward a higher percentage of CD4 T cells (Fig. 1) and a higher overall marrow cellularity (median 62.5% vs. 55% nonfat cells among fat plus nonfat cells at week 4 and 72.5% vs. 40% at week 8). In the lymph nodes at week 8, the percentage of CD4 T cells was similar (Fig. 1) , while there was a trend toward larger lymph node volume in IL7-than placebotreated animals (Fig. 2) . These results suggest that IL7 treatment increased the number of total body CD4 T cells.
The conclusion that IL7 stimulated peripheral expansion rather than de novo generation was further supported by the determination of the volumes of thymi, spleens, and lymph nodes (Fig. 2) . There was a trend toward higher median increase of splenic volume (30, On each x-axis, bPre-TxQ denotes pretransplant, bPre-IL7Q denotes immediately pre-IL7/placebo treatment, and subsequent numbers denote weeks after starting IL7/placebo treatment. The period of IL7 treatment is indicated in each graph by the black horizontal bar. The TREC + CD4 T cell counts could not be reliably enumerated immediately before and in the first 3 weeks of IL7/placebo treatment due to low total CD4 counts; b0.01Q is arbitrarily displayed for the immediate pretreatment time point. BM denotes bone marrow, and LN denotes lymph nodes. In both organs, the percentages are among total nucleated cells and were determined by flow cytometry. For a clearer interpretation of this figure, the reader is referred to the figure in the Web version of this article. necropsy findings on the animal that died 1 day before the week 8 evaluation (Z00158); its spleen and lymph nodes were larger, and its thymus was smaller than normal (per pathologist blinded to the treatment-D.H.L. , and CD4 À CD8 + thymocytes), the thymus of Z00158 as well as the thymi of the other two IL7-treated and one placebotreated animals subjected to thymic biopsy at week 8 appeared normal. The conclusion that IL7 stimulated peripheral expansion rather than de novo generation was also supported by the fact that there appeared to be no difference in the percentage of TREC-containing cells among lymph node CD4 T cells at week 8. This was determined in two IL7-and two placebo-treated animals, and the average was 11% versus 12%, respectively.
IL7 had no significant effect on blood counts or lymph node percentages of CD8 T cells, B cells, monocytes, or NK cells (data not shown).
IL7 treatment increased the number of CMV-specific CD4 T cells
Symptomatic herpesviral disease occurs in CD4 lymphopenic patients, particularly those with low counts of herpesvirus-specific CD4 T cells [3, 15, 23] . We asked whether herpesvirus-specific CD4 T cells are increased with IL7. CMV was used as a prototype herpesvirus because baboon CMV infection of baboons closely resembles human CMV infection of humans [24] and because we could identify baboon CMV-specific CD4 T cells in baboons as CD4 T cells producing IFNg when stimulated with baboon CMV antigens (Fig. 3, top) . Because total CD4 T cell counts were low, CMV-specific CD4 T cells could not be reliably enumerated immediately pre-IL7/placebo treatment (zero values are arbitrarily displayed in Fig. 3 , bottom left) and could not be always enumerated in the first 6 weeks or treatment, especially in the placebo-treated animals. Nevertheless, a complete set of data was available for the end of treatment (weeks 7-8). At that time point, median CMV-specific CD4 T cell counts were significantly higher in IL7 than placebotreated animals (median 122 vs. 1/Al, P = 0.03). Thus, IL7 treatment increased anti-CMV CD4 T cells.
The IFNg-producing CD4 T cells typically produced also TNFa (Fig. 3, bottom right) . In 18 specimens studied (from pretransplant and various time points posttransplant), percent CD4 T cells producing TNFa (alone or together with IFNg) correlated with the percent of CD4 T cells producing IFNg (alone or together with TNFa) (Spearman rank correlation coefficient R = 0.90, P b 0.001). A similar correlation was found in macaque CMV-infected macaques [25] . Therefore, it is likely that counts of not only IFNg-producing anti-CMV CD4 T cells but also TNFa-producing anti-CMV CD4 T cells were higher in IL7 than placebo-treated animals. Fig. 2 . Volumes of thymus, spleen, and lymph nodes (LN) in IL7-treated (black) and placebo-treated (gray) animals pretransplant (Pre-Tx), immediately pre-IL7/placebo treatment (Pre-IL7), and 8 and 20 weeks after starting IL7/placebo. Each LN volume represents the sum of volumes of one right axillary LN, one left axillary lymph node, one pelvic LN, one right inguinal LN, and one left inguinal lymph node. IL7 treatment period is indicated by the horizontal black bar. The animals subjected to thymic biopsy at week 8 (after the CT scan) had the following symbols: black asterisks, black circles, and gray circles. Note that, at the last follow-up, five of six animals reached a higher thymic volume than pretransplant; the one animal that did not reach pretransplant thymic volume (gray circles) may have not done so due at least in part to the biopsy at week 8. For a clearer interpretation of this figure, the reader is referred to the figure in the Web version of this article.
After transplantation in humans, recovery of CMVspecific T cells is boosted by CMV reactivation (detection of CMV in posttransplant blood using a technique that usually does not detect CMV in blood from normal seropositive individuals, for example, pp65 immunostaining) [26] [27] [28] . In our experiment, CMV reactivation could have occurred in the IL7-treated and not in the placebotreated baboons. If true, the higher counts of CMV-specific CD4 T cells in the IL7-treated baboons could be due to CMV reactivation and not necessarily due to IL7. Contrary to that, reactivation of CMV during IL7/placebo treatment was documented in all (both IL7-and placebo-treated) baboons (Fig. 4) . Therefore, the increased number of CMVspecific CD4 T cells in the IL7-treated animals was likely due to IL7.
Potential toxicity of IL7
One animal (Z00158) died unexpectedly at the end of IL7 administration (1 day before the scheduled week 8 Fig. 3 . IL7 treatment increased CMV-specific CD4 T cells. At the top, examples of CD4 versus IFNg dotplots from the end of treatment (week 7 or 8) are displayed, showing the trend toward higher percentages of CMV-specific IFNg-producing CD4 T cells (among total CD4 T cells) in IL7-than placebotreated animals. The bNormalQ blood was obtained pretransplant. Blood MNCs were stimulated with CMV lysate prepared from infected MRC5 cells and processed as described in the Materials and methods. Stimulation with uninfected MRC5 lysate resulted in less than 0.05% IFNg-producing CD4 cells (not shown); this was subtracted when calculating the absolute number of CMV-specific CD4 T cells displayed below. In each dotplot, the gate is set on CD4 lymphocytes, and 10,000 events are displayed. At the bottom left, the absolute numbers of CMV-specific CD4 T cells in IL7 (black)-and placebo (gray)-treated baboons are shown. IL7 treatment period is indicated by the horizontal black bar. CMV-specific cells could not be reliably enumerated immediately pre-IL7/ placebo treatment; b0Q is arbitrarily displayed for each animal. At the bottom right, a typical TNFa versus IFNg dotplot gated on CD4 lymphocytes is displayed, showing that most IFNg CD4 T cells produced also TNFa. For a clearer interpretation of this figure, the reader is referred to the figure in the Web version of this article. evaluation). The only clinical symptom or sign noted was anorexia in the last week of life, attributed to mild renal insufficiency (serum creatinine rose from baseline 0.5-1.0 mg/dl to maximum 1.6 mg/dl). On necropsy, macroscopic findings included large lymph nodes and spleen, small thymus, marginally enlarged kidneys with pale, radial streaks in the cortex, and firm and nonfloating lungs. Microscopically, most organs were infiltrated with CD3 + cells. The infiltration was most prominent in the lungs and the kidneys (Fig. 5, top) . Approximately one half of the cells infiltrating the kidneys and the lungs were CD4 + and one half CD8 + . No inclusions or syncytia were noted, suggesting autoimmune rather than viral etiology. Of the total of nine baboons we have treated with IL7, death associated with T cell infiltration of multiple organs occurred in two animals (A00066 reported in Ref. [11] and Z00158 reported here). This complication may have resulted from overtreatment, as we continued to give IL7 to animals per protocol even after they have reached a high CD4 T cell count. The death occurred in two of five animals that reached a CD4 T cell count of greater than 2,500/Al and none of four animals that did not reach CD4 T cell count of 2500/Al. CD8 T cell counts and the deaths appeared to be unrelated.
Because of the renal dysfunction of Z00158 premortem with the postmortem finding of T cell infiltration of the kidneys reported here and because of a mild kidney enlargement from immediately pre-IL7 to the end of 4-week treatment noted on CT in all five animals treated with IL7 in our previous experiment [11] (unpublished), we retrospectively measured kidney volumes of the three surviving IL7-treated and the three placebo-treated animals in the present experiment (Fig. 5, bottom) . Median increase in the kidney volume was 31,155 mm 3 in the IL7-treated group compared to À4301 mm 3 in the Fig. 5 . Extensive lung (top) and kidney (center) infiltration with CD3 + cells (brown). This was found on the necropsy of animal Z00158 that died 1 day before week 8 evaluation. In the lungs, the T cells were localized primarily around blood vessels (asterisks), but also around bronchioles and in the parenchyma. In the kidneys, the T cells were localized also primarily around blood vessels (asterisks), but also around tubules and glomeruli. Among the surviving animals, kidney enlargement (bilateral) at week 8 of treatment was found in the IL7-treated but not the placebo-treated animals (bottom). The kidney volume is a composite volume of right and left kidneys. Image (top and center) information: Nikon E-400 microscope, Nikon 10Â lens with 0.25 numerical aperture, digital imaging medium, Nikon Coolpix 5000 camera with Nikon software, Microsoft Photo Editor (for adjustment of general brightness and contrast only-no other operations performed). placebo-treated group. Concurrent rise in serum creatinine was not observed. The kidney volume returned close to baseline within 3 months after discontinuation of IL7. We speculate that the kidney enlargement was due to T cell infiltration, although histology was only available for Z00158.
Thrombocytopenia and possibly neutropenia and anemia were associated with IL7 treatment in the previous experiment. In this experiment, we observed a trend toward lower hematocrit and platelet counts (Fig. 6) but not neutrophil counts (data not shown) in IL7-than placebo-treated animals. Perhaps, the hematologic toxicity in this experiment was not as obvious as in the previous experiment because one of the placebo-treated animals had an unusually poor engraftment (gray squares in Fig. 6 ).
Osteoporosis due to stimulation of osteoclasts developed after only 20 days of treatment with IL7 in mice. [29] . In our previous baboon experiment, treatment with IL7 for 28 days was not associated with decreased bone density. In the present experiment, treatment for 56 days was also not associated with decreased bone density (Fig. 7) .
Lymphoma did not develop in the three IL7-treated animals that did not die unexpectedly. This was determined by both CT and necropsy at 3 months after discontinuation of IL7.
IL7 levels and IL7 neutralizing antibodies
Median serum IL7 level (of all seven animals) rose from 6 pg/ml pretransplant to 27 pg/ml immediately pre-IL7/ placebo treatment, reflecting endogenous response to the severe CD4 lymphopenia (Fig. 8) . In the IL7-treated animals, IL7 levels approximately 3 logs higher than at baseline (pretransplant) were reached within 1 week and were maintained throughout the remaining 7 weeks of treatment. In the placebo-treated animals, IL7 levels returned to baseline within approximately 1 month.
IL7 neutralizing antibodies may have theoretically been generated in the IL7-treated animals, although the IL7 was species-specific, as human cytokine neutralizing antibodies have developed in humans treated with erythropoietin, GM-CSF and thrombopoietin [30] [31] [32] , and IL7 might stimulate antibody production by stimulating helper T cells. Therefore, sera from all four IL7-treated baboons Fig. 6 . Hematocrit and platelet counts in IL7 (black)-and placebo (gray)-treated baboons. The high hematocrit immediately pre-IL7/placebo treatment is a result of overtransfusion (using whole blood for thrombocytopenia) in the first 6 weeks after transplant. The sudden increases in hematocrit in the animal denoted by black triangles between 2 and 3 weeks and in the animal denoted by gray squares between 3 and 4 weeks into IL7/ placebo treatment resulted from blood transfusions. The sudden drop in hematocrit in the animal denoted by gray squares between weeks 14 and 15 resulted from babesiosis, and the subsequent rise in hematocrit coincided with doxycycline treatment. As in Fig. 1 , bPre-TxQ denotes pretransplant, bPre-IL7Q denotes immediately pre-IL7/placebo treatment, and subsequent numbers denote weeks after starting IL7/placebo treatment. The period of IL7 treatment is indicated by the black horizontal bar. For a clearer interpretation of this figure, the reader is referred to the figure in the Web version of this article. collected at the end of IL7 treatment were assayed for the presence of IL7 neutralizing antibodies. None were detected.
Discussion
This study shows that, even in the setting of severe lymphopenia and with 8-week treatment (longer than previously reported), IL7 does not substantially stimulate thymopoiesis. The positive finding of this study is that IL7 administered to primates expands anti-CMV CD4 T cells that are functional (produce IFNg and TNFa when stimulated). This gives hope that IL7 administered to patients will expand antiviral or antitumor CD4 T cells capable of producing IFNg and TNFa. IFNg-or TNFaproducing CD4 T cells can directly kill virus-infected or tumor cells [15, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Virus/tumor-specific CD4 T cells may also facilitate protection against viral disease or cancer indirectly by sustaining virus/tumor-specific cytotoxic CD8 T cells (reviewed in Ref. [14] ). Major application of IL7 will likely be in immunotherapy. For example, after high-dose chemo/radiotherapy for cancer with autologous transplantation of CD34 cells (purified to minimize the likelihood of reinfusing tumor cells), T cells specific for the cancer and for viruses that may cause disease after autologous CD34 cell transplantation like CMV [45] or Epstein-Barr virus [46] could be infused and expanded in vivo by the administration of IL7. In herpes simplex virus-infected mice treated with antiviral T cells, IL7 treatment resulted in 20-fold reduction in viral load compared to controls treated with antiviral T cells alone [47] .
Regarding potential toxicities of IL7, it is reassuring that even after 8-week treatment, lymphoma (detectable as a mass on CT or necropsy) or osteoporosis did not develop, and anemia and thrombocytopenia appeared to be mild. However, the two deaths associated with T cell infiltration of multiple organs, occurring in nine IL7-treated baboons, are of concern. In both cases, the organs were infiltrated with both CD4 and CD8 T cells, suggesting against monoclonal/malignant lymphoproliferation. Viral etiology is also unlikely as no inclusions or syncytia were noted on H and E-stained sections of the most involved organs (intestines in the first case and lungs and kidneys in the second case) or other organs. Direct autoimmune damage of organs by the infiltrating T cells is a plausible mechanism; in the first case, the T cells were concentrated in the areas of damaged intestinal crypts (Fig. 10 in Ref. [11] ). Alternatively, the IL7-expanded T cells may have secreted other cytokines, leading to a bcytokine storm.Q This would be reminiscent of interleukin-2 toxicity which appears to be mediated through the release of secondary cytokines like TNF, IFNg, interleukin-1, and interleukin-6 [48] . The latter mechanism is less likely as in normal monkeys treated with IL7 (up to 1200 Ag/kg/day for less than 1 month) for the determination of IL7 toxicity, no increase in serum levels of TNFa, IFNg, or interleukin-6 was observed (M. Morre, personal communication, March 2004). Despite the fact that the pathogenesis of the death associated with T lymphoproliferation has not been elucidated, the important observation is that it may be related to the degree of the IL7-induced CD4 T cell expansion. The deaths occurred in two of five animals whose CD4 T cell count during IL7 treatment exceeded 2500/Al and in none of four animals with lower maximum CD4 T cell count during IL7 treatment. Among 21 normal 2-year-old baboons in which we determined CD4 T cell counts, the two highest counts were 2005 and 2130/Al. Our suggestion for the design of clinical trials is to monitor CD4 T cell counts during IL7 treatment and either discontinue IL7 or proceed with extreme caution after the CD4 T cell count has exceeded the upper normal limit.
In conclusion, given the potential for increasing the number of functional antiviral or antitumor T cells, clinical testing of IL7 is indicated. Analogous to the fact that life-threatening side effects of erythropoietin (e.g., occlusion of a cerebral vessel) occur in patients reaching high erythrocyte counts and those of filgrastim (e.g., dyspnea associated with pulmonary X-ray infiltrates) occur in patients reaching high granulocyte counts, it is possible that life-threatening side effects of IL7 may occur in patients reaching high CD4 T cell counts. Fig. 1 , bPre-TxQ denotes pretransplant, bPre-IL7Q denotes immediately pre-IL7/placebo treatment, and subsequent numbers on the xaxis denote weeks after starting IL7/placebo treatment. The period of IL7 treatment is indicated by the black horizontal bar. For a clearer interpretation of this figure, the reader is referred to the figure in the Web version of this article.
